Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-09-08
1995-07-25
Warden, Jill
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, A61K 3100, A61K 3148, A61K 31245, A61K 31175
Patent
active
054362300
DESCRIPTION:
BRIEF SUMMARY
The subject of the present invention is the use of a growth factor as the active principle in the preparation of a slimming and lipolytic composition and its application in a method of treatment for improving the aesthetic appearance of the skin. The present invention is also directed to a slimming composition containing a growth factor combined with another lipolytic substance such as caffeine.
BACKGROUND OF THE INVENTION
Growth factors are polypeptide molecules shown by in vivo and in vitro studies to multiply and differentiate cells of different origins and species. For some of these growth factors, it has been possible to determine the amino acid sequence and the structure of the corresponding gene. Among tissue growth factors, which were studied in depth because of the multiplicity of the target cells concerned, or the biological effects observed, and because of the therapeutic impact that physicians and particularly dermatologists may expect, it should be mentioned in particular, Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF) and Eye Derived Growth Factor (EDGF).
The expression "growth factor" is also understood to mean mixtures of growth factors, particularly that derived from nerve tissue, hereinafter called m-NTGF (mixture of Nervous Tissue Growth Factors) as well as other peptides or polypeptides with a growth factor character of natural or synthetic origin.
Growth factors have a stimulating effect on cell proliferation, particularly that of epithelial cells, and have proved effective in the scarring of lesions.
Some of these growth factors are used in cosmetology for skin care as described for example in French Patent Application No. 79.31731 (Publication No. 2.472.385) and particularly in its Certificate of Addition No. 82.15559 (Publication No. 2.533,438). However, in these references their mitogenic activity is assumed to render these factors useful in skin care.
The studies on EGF that may be mentioned in particular are the articles by G. Carpenter et al., Ann. Rev. Biochem., 48, 193-216 (1979) and L. E. King et al., Progress in Dermatology, Vol. 19, No. 1, 1-8 (1985).
Among the studies on FGF, particular mention may be made of the articles by D. Gospodarowicz et al., J. Cell, Physiol. Supp., 5/15-26 (1987), and Gary D. Shipley, et al., J. Cell. Physiol. 138/511-518 (1989).
Among the articles on EDGF, reference may be made to the articles by D. Barritault, et al., Journal of Neuroscience Research, 8:477-490 (1982) and A. Y. Fourtanier, et al., The Journal of Investigative Dermatology, Vol. 87, No. 1, 76-80 (1986).
It has now been discovered quite unexpectedly that these growth factors have a lipolytic effect and can be used as active principles in slimming compositions.
It has been found in particular that these growth factors may be used to combat cellulitis and local fat overload.
It is known that swelling of the subcutaneous connective tissue, known as cellulitis, gives the skin an "upholstered" appearance. Cellulitis is formed by local accumulation of fat and water trapped in a matrix of more or less fluid-tight compartments.
BRIEF DESCRIPTION OF THE DRAWINGS
Topical application of an anticellulitic agent may erase local accumulation of fat by lipolytic action. The best-known and most widespread method of stimulating lipolysis is by inhibiting phosphodiesterase to prevent or at least limit the rate of cyclic AMP breakdown. Phosphodiesterase destroys cyclic AMP converting it into 5' AMP so that it is unable to activate lipolysis. Hence the point is to inhibit the action of phosphodiesterase to achieve a high level of cyclic AMP in the adipocytes in order to stimulate lipolytic activity.
Among the various phosphodiesterase inhibitors recommended as slimming agents, xanthine bases, particularly caffeine, may be mentioned in particular. However, caffeine, particularly at high concentrations, is not always tolerated, even topically, because it penetrates and may give rise to palpitations in certain particularly sensitive subjects. It has now been quite unexpectedly discov
REFERENCES:
patent: 4525359 (1985-06-01), Greenway, III
patent: 4645828 (1987-02-01), Twardzik
patent: 5030451 (1991-07-01), Trebosc
patent: 5180820 (1993-01-01), Barde
patent: 5215759 (1993-06-01), Mausner
Carpenter, G. et al., "Epidermal Growth Factor", Ann. Rev. Biochem. (1979), 48:193-216.
King, L., "Progress in Dermatology", vol. 19, No. 1, Mar. 1985, pp. 1-8.
Gospodarowicz, G., "Fibroblast Growth Factor: Structural and Biological Properties", J. of Cell. Phys. Supplement. 5:15-26 (1987).
Shipley, G. et al. "Growth of Normal Human Keratinocytes and Fibroblasts in Serum-Free Medium is Stimulated by Acidic and Basic Fibroblast Growth Factor", J. of Cell. Phys., 138-511-518 (1989).
Barritault, D. et al., "Purification, Characterization, and Biological Properties of the Eye-Derived Growth Factor from Retina: Analogies with Brain-Derived Growth Factor", Journal of Neuroscience Research, 8:477-490 (1982).
Fourtainer, A. et al. "Eye-Derived Growth Factor Isolated from Bovine Retina and Used for Epidermal Wound Healing in Vivo", The Journal of Investigative Dermatology, vol. 87, No. 1, Jul. 1986, pp. 76-80.
Tran et al., European J. of Pharmacology, vol. 76, pp. 435-438 (1981).
The Merck Manual of Diagnosis and Therapy, 5th ed., Robert Berkow, Editor, Merck and Co., Inc. Rahway, N.J. 1987, pp. 950-955.
O'Sullivan, U., et al., "Insulin-like Growth Factor-1 (IGF-1) in Mice Reduces Weight Loss During Starvation", Endocrinology, vol. 125, No. 5, Nov. 1989, The Endocrine Society (U.S.), pp. 2793-2794.
Nadaud Jean-Francois
Soudant Etienne
"L'Oreal"
Touzeau Lynn
Warden Jill
LandOfFree
Use of a growth factor in a slimming composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a growth factor in a slimming composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a growth factor in a slimming composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-739688